However, in individuals with hypertriglyceridemia, evolocumab played a modest role in lowering TG levels [14, 15], indicating that anti-PCSK9 mAbs may impact TG levels in a dose-dependent manner. Here, PCSK9 is linked to hypertriglyceridemia.